212 related articles for article (PubMed ID: 18332872)
21. The incidence of topoisomerase II-alpha genomic alterations in adenocarcinoma of the breast and their relationship to human epidermal growth factor receptor-2 gene amplification: a fluorescence in situ hybridization study.
Hicks DG; Yoder BJ; Pettay J; Swain E; Tarr S; Hartke M; Skacel M; Crowe JP; Budd GT; Tubbs RR
Hum Pathol; 2005 Apr; 36(4):348-56. PubMed ID: 15891995
[TBL] [Abstract][Full Text] [Related]
22. Outcome of patients with early-stage breast cancer treated with doxorubicin-based adjuvant chemotherapy as a function of HER2 and TOP2A status.
Tubbs R; Barlow WE; Budd GT; Swain E; Porter P; Gown A; Yeh IT; Sledge G; Shapiro C; Ingle J; Haskell C; Albain KS; Livingston R; Hayes DF
J Clin Oncol; 2009 Aug; 27(24):3881-6. PubMed ID: 19620488
[TBL] [Abstract][Full Text] [Related]
23. Amplification and overexpression of the ABCC3 (MRP3) gene in primary breast cancer.
Partanen L; Staaf J; Tanner M; Tuominen VJ; Borg Å; Isola J
Genes Chromosomes Cancer; 2012 Sep; 51(9):832-40. PubMed ID: 22585709
[TBL] [Abstract][Full Text] [Related]
24. Assessment of topoisomerase II-alpha gene status by dual color chromogenic
Neama RAA; Habib MA; Ali SA; Al-Khafaji AH; Alqanbar MF
Indian J Pathol Microbiol; 2017; 60(4):475-480. PubMed ID: 29323058
[TBL] [Abstract][Full Text] [Related]
25. HER-2, TOP2A and chromosome 17 alterations in breast cancer.
Beser AR; Tuzlali S; Guzey D; Dolek Guler S; Hacihanefioglu S; Dalay N
Pathol Oncol Res; 2007; 13(3):180-5. PubMed ID: 17922046
[TBL] [Abstract][Full Text] [Related]
26. Characterization of topoisomerase II alpha gene amplification and deletion in breast cancer.
Järvinen TA; Tanner M; Bärlund M; Borg A; Isola J
Genes Chromosomes Cancer; 1999 Oct; 26(2):142-50. PubMed ID: 10469452
[TBL] [Abstract][Full Text] [Related]
27. Quantification and clinical relevance of gene amplification at chromosome 17q12-q21 in human epidermal growth factor receptor 2-amplified breast cancers.
Lamy PJ; Fina F; Bascoul-Mollevi C; Laberenne AC; Martin PM; Ouafik L; Jacot W
Breast Cancer Res; 2011 Feb; 13(1):R15. PubMed ID: 21288332
[TBL] [Abstract][Full Text] [Related]
28. Predictive markers of anthracycline benefit: a prospectively planned analysis of the UK National Epirubicin Adjuvant Trial (NEAT/BR9601).
Bartlett JM; Munro AF; Dunn JA; McConkey C; Jordan S; Twelves CJ; Cameron DA; Thomas J; Campbell FM; Rea DW; Provenzano E; Caldas C; Pharoah P; Hiller L; Earl H; Poole CJ
Lancet Oncol; 2010 Mar; 11(3):266-74. PubMed ID: 20079691
[TBL] [Abstract][Full Text] [Related]
29. HER2 and TOP2A Gene Amplification and Protein Expression in Upper Tract Urothelial Carcinomas.
Aumayr K; Klatte T; Neudert B; Birner P; Shariat S; Schmidinger M; Susani M; Haitel A
Pathol Oncol Res; 2018 Jul; 24(3):575-581. PubMed ID: 28755093
[TBL] [Abstract][Full Text] [Related]
30. Association between HER2, TOP2A, and response to anthracycline-based preoperative chemotherapy in high-risk primary breast cancer.
Konecny GE; Pauletti G; Untch M; Wang HJ; Möbus V; Kuhn W; Thomssen C; Harbeck N; Wang L; Apple S; Jänicke F; Slamon DJ
Breast Cancer Res Treat; 2010 Apr; 120(2):481-9. PubMed ID: 20130985
[TBL] [Abstract][Full Text] [Related]
31. HER2 and TOP2A amplification in a hospital-based cohort of breast cancer patients: associations with patient and tumor characteristics.
Fasching PA; Weihbrecht S; Haeberle L; Gasparyan A; Villalobos IE; Ma Y; Ekici AB; Wachter DL; Hartmann A; Beckmann MW; Slamon DJ; Press MF
Breast Cancer Res Treat; 2014 May; 145(1):193-203. PubMed ID: 24682655
[TBL] [Abstract][Full Text] [Related]
32. Unraveling the chromosome 17 patterns of FISH in interphase nuclei: an in-depth analysis of the HER2 amplicon and chromosome 17 centromere by karyotyping, FISH and M-FISH in breast cancer cells.
Rondón-Lagos M; Verdun Di Cantogno L; Rangel N; Mele T; Ramírez-Clavijo SR; Scagliotti G; Marchiò C; Sapino A
BMC Cancer; 2014 Dec; 14():922. PubMed ID: 25481507
[TBL] [Abstract][Full Text] [Related]
33. Topoisomerase IIalpha gene (TOP2A) amplification and deletion in cancer--more common than anticipated.
Järvinen TA; Liu ET
Cytopathology; 2003 Dec; 14(6):309-13. PubMed ID: 14632727
[TBL] [Abstract][Full Text] [Related]
34. Analysis of EGFR, HER2, and TOP2A gene status and chromosomal polysomy in gastric adenocarcinoma from Chinese patients.
Liang Z; Zeng X; Gao J; Wu S; Wang P; Shi X; Zhang J; Liu T
BMC Cancer; 2008 Dec; 8():363. PubMed ID: 19061514
[TBL] [Abstract][Full Text] [Related]
35. Prognostic value of TOP2A gene amplification and chromosome 17 polysomy in early breast cancer.
Zaczek A; Markiewicz A; Supernat A; Bednarz-Knoll N; Brandt B; Seroczyńska B; Skokowski J; Szade J; Czapiewski P; Biernat W; Wełnicka-Jaśkiewicz M; Jassem J
Pathol Oncol Res; 2012 Oct; 18(4):885-94. PubMed ID: 22426810
[TBL] [Abstract][Full Text] [Related]
36. Adjuvant docetaxel and cyclophosphamide plus trastuzumab in patients with HER2-amplified early stage breast cancer: a single-group, open-label, phase 2 study.
Jones SE; Collea R; Paul D; Sedlacek S; Favret AM; Gore I; Lindquist DL; Holmes FA; Allison MAK; Brooks BD; Portillo RM; Vukelja SJ; Steinberg MS; Stokoe C; Crockett MW; Wang Y; Asmar L; Robert NJ; O'Shaughnessy J
Lancet Oncol; 2013 Oct; 14(11):1121-1128. PubMed ID: 24007746
[TBL] [Abstract][Full Text] [Related]
37. Triple negative breast cancer--current status and prospective targeted treatment based on HER1 (EGFR), TOP2A and C-MYC gene assessment.
Bouchalova K; Cizkova M; Cwiertka K; Trojanec R; Hajduch M
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2009 Mar; 153(1):13-7. PubMed ID: 19365520
[TBL] [Abstract][Full Text] [Related]
38. Gene copy mapping of the ERBB2/TOP2A region in breast cancer.
Jacobson KK; Morrison LE; Henderson BT; Blondin BA; Wilber KA; Legator MS; O'Hare A; Van Stedum SC; Proffitt JH; Seelig SA; Coon JS
Genes Chromosomes Cancer; 2004 May; 40(1):19-31. PubMed ID: 15034864
[TBL] [Abstract][Full Text] [Related]
39. TOP2A and HER-2 gene amplification in fine needle aspirates from breast carcinomas.
Bofin AM; Ytterhus B; Hagmar BM
Cytopathology; 2003 Dec; 14(6):314-9. PubMed ID: 14632728
[TBL] [Abstract][Full Text] [Related]
40. TOP2A amplification in breast cancer is a predictive marker of anthracycline-based neoadjuvant chemotherapy efficacy.
Wang J; Xu B; Yuan P; Zhang P; Li Q; Ma F; Fan Y
Breast Cancer Res Treat; 2012 Sep; 135(2):531-7. PubMed ID: 22864769
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
